Lantern Pharma secures Taiwan clearances for Phase II NSCLC study

Lantern Pharma has secured regulatory and IRB clearances in Taiwan to initiate Part 2 of its Phase II HARMONIC clinical trial of LP-300 in combination with carboplatin and pemetrexed in never-smokers with advanced NSCLC. Under the amended protocol, eligible participants may receive up to eight LP-300 cycles, increased from the previous limit. Lantern expects two further Taiwanese sites to gain ethics approvals during the fourth quarter. Credit: THICHA SATAPITANON/Shutterstock.com. Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase II HARMONIC clinical trial of LP-300 in combination with carboplatin and…

Source: Clinical Trials Arena